Gilead Sciences (GILD) Tops Q2 EPS by 35c

Go back to Gilead Sciences (GILD) Tops Q2 EPS by 35c

Gilead Sciences (GILD) PT Raised to $85 at Morgan Stanley

July 26, 2018 8:53 AM EDT

Morgan Stanley raised its price target on Gilead Sciences (NASDAQ: GILD) to $85.00 (from $81.00) while maintaining a Equalweight rating.

... More

Gilead Sciences (GILD) PT Raised to $90 at RBC Capital

July 26, 2018 7:58 AM EDT

RBC Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $87.00) while maintaining an Outperform rating following results.

Analyst Brian Abraham commented, "With strong HIV sales and HCV stabilizing, GILD seems to be tracking towards steadier earnings base upon which... More